We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Handheld Micro-Laboratory to Enable Ambulant Multi-Parameter Blood Coagulation Analysis

By LabMedica International staff writers
Posted on 07 Nov 2022

Hemophilia is a rare genetic disorder that is estimated to affect over 800,000 people worldwide. More...

Those with hemophilia A lack sufficient blood- clotting factor VIII (FVIII) activity, causing them to bleed for longer after an injury compared to healthy subjects. Due to the complexities associated with managing the condition, patients benefit from being able to safely monitor their condition at home while potentially staying connected with their care team by telemedicine. Now, a breakthrough ambulant diagnostic technology for blood coagulation testing will enable hemophilia patients to determine and monitor their coagulation status from home in real-time.

Enzyre B.V. (Nijmegen, The Netherlands) is developing its unique diagnostic technology platform, EnzyPad, which will enable hemophilia patients to self-test in a home setting, and eventually transfer their coagulation status to their treating physician through a mobile phone app and a cloud- based application. This will allow for timely personalized therapy adjustments that may improve clinical outcomes while avoiding unnecessary travel and hospital exposure, ultimately decreasing overall treatment burden and cost for patients and healthcare systems.

EnzyPad has only four components: blood sampling device (TAP in case of haemophilia), microfluidic cartridge (EnzyCard), processor (EnzyPad) and a mobile phone with the ENZY app. As it is the size of a small tablet, EnzyPad is easily portable and fits into a small backpack together with several EnzyCards. Each EnzyCard contains reagents and appropriate controls to perform several coagulation tests in parallel on a single blood sample. The results have the same quality as if performed on a large instrument in a specialized laboratory and are available in real-time right next to the patient who can get the optimal therapy without any delay.

In order to find the cause of a bleed, in most cases it is necessary to determine several parameters simultaneously. As a single EnzyCard can handle up to sixteen tests in parallel, there is ample space for multiple assays and corresponding controls. The EnzyPad will encrypt the data of the test results and transfer them via a Bluetooth connection to a mobile phone app, that will place the data in the cloud where anyone with the appropriate credentials can access them. The first EnzyPad products will be focused on blood coagulation, although the technology can be applied much more broadly in collaboration with partners that have expertise in different fields.

Related Links:
Enzyre B.V.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.